Philips Wake-Up Light Alarm Clock
Philips Wake-Up Light Alarm Clock
The Department of Labor released its weekly report on new jobless claims Thursday at 8:30 a.m. ET.
Canadian energy company Pieridae Energy Ltd said on Thursday it still expects to make a final investment decision by June 30 on its proposed Goldboro liquefied natural gas (LNG) export plant in Nova Scotia. Pieridae is one of several firms to have delayed projects to build North American LNG export plants as global gas prices fell to their lowest in years in an oversupplied market in 2019 and then to record lows in 2020 after a coronavirus-induced demand collapse. “Goldboro ... is beginning to look like ‘the last one standing’ with others in North America either being delayed or canceled outright," Pieridae Chief Executive Alfred Sorensen said in the company's first-quarter earnings release.
Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced the company has officially established its U.S. operations with the appointment of Patrick M. Shea as Chief Executive Officer and member of the Board of Directors. Mr. Shea will be responsible for building the company’s operational and business structure and initiating the U.S. clinical development program for its fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The product is currently marketed as Lecigon™ in the Nordic countries and certain European markets.
Atlas Corp. ("Atlas") (NYSE: ATCO) today announced the final results of its previously announced offer to exchange (the "Exchange Offer") up to $80,000,000 aggregate principal amount of 7.125% Notes due 2027 (the "ATCO Notes"), which have been registered under the Securities Act of 1933, as amended, for any and all outstanding $80,000,000 aggregate principal amount of 7.125% Notes due 2027 of its subsidiary, Seaspan Corporation (the "Seaspan Notes"). The Seaspan Notes were originally issued in October 2017. The Exchange Offer expired at 5:00 pm New York City time on Wednesday, May 12, 2021 and will be settled on Monday, May 17, 2021 (the "Settlement Date").
New York, New York--(Newsfile Corp. - May 13, 2021) - PCG Digital -- Things seem to be heating up for (NASDAQ: AIKI) with a near term potential catalyst quickly approaching this quarter and several others planned throughout the remainder of the year. Management has been filing form 4s showing open market buying which typically signals strong faith in the company and signifies how undervalued they believe the stock may be at these levels. Speaking ...
Berwyn, Pennsylvania--(Newsfile Corp. - May 13, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive orphan drug designation for its lead drug candidate, ANVS401, for the treatment of AD in persons with Down syndrome (DS), referred to as DS-AD.DS occurs in about ...
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2021) - Cross River Ventures Corp. (CSE: CRVC) (FSE: C6R) (the "Company") is pleased to report that field work, including prospecting and focused mapping, has commenced at its 100% owned, 6,570-hectare, Manitou Gold Project, located within the Archean Uchi Subprovince, NW Ontario, Canada.Bayside Geoscience has been contracted to conduct a 2-week reconnaissance program at the Manitou property. This Phase 1 field campaign will focus on assessing gold-bearing ...
Renoworks Software Inc. (TSXV: RW) ("Renoworks" or the "Company), the leading end-to-end visualization platform for the home remodeling and new home construction industry, announced financial results for the first quarter ended March 31, 2021. The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com. Unless otherwise stated, all dollar amounts are Canadian dollars.
RIDGEFIELD PARK, NEW JERSEY, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- LIFEQUEST WORLD CORP (LQWC) subsidiary, Biopipe Global Corp., which developed the world’s only highly scalable onsite sludge, odor and chemical free sewage wastewater treatment technology, is pleased to announce that its joint venture in Bangladesh has received two new orders for a 100m3/day plant for a government building and 180m3/day plant for a hotel. Ekram Zaman, Executive Director of Biopipe Innovation, our joint venture in Bangladesh, said, “In spite of severe Covid-19 situation, we are pleased to close two additional orders -- one for a government office building and the other for a hotel. Once commissioned, the hotel plant will help us pursue the hospitality sector more aggressively. Several tenders have been delayed due to lockdown, but we are confident that we will win those tenders once they come back on line.” Max Khan, CEO of Lifequest, said, “Covid-19 has impacted commercial activity in our key markets but we continue to gain traction in Bangladesh. We are expecting additional orders in the near future. With capex decisions postponed due to lockdown, we are vigorously working to implement our Build Own Operate and Build Own Lease Transfer strategy in South Africa and Turkey. We are also expecting a decision soon on a large government tender we qualified for in Ethiopia.” About Lifequest & Biopipe Lifequest offers both effluent treatment (ETP) and sewage treatment (STP) solutions. Biopipe, a wholly owned subsidiary, has developed a patented 100% sludge-free, chemical-free, odor-free, silent, easy to assemble and install, scalable, low cost, ecological and virtually maintenance-free onsite sewage wastewater treatment system. It treats both grey and black water. The treated water exceeds EU and all local standards for discharge and can be reused for irrigation, flushing and cleaning. Our Abrimix ETP solution is a highly efficient and cost-effective industrial wastewater treatment system that is vastly superior to Dissolved Air Floatation (DAF) systems. www.lifequestcorp.com https://www.biopipe.co/ Contact: email@example.com Biopipe Innovation, Bangladesh Name: Ekram Zaman Email: firstname.lastname@example.org Phone: +880 1711991276 This press release contains forward-looking statements that reflect the Company's current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "will," "will be," "anticipate," "predict," “expect” "continue," "future," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: future revenues, expenditures, capital, the adequacy of the Company's current cash and working capital to fund present and planned operations, and the growth through joint ventures. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, can be found in our current Disclosure Statements at www.otcmarkets.com. The Company anticipates that subsequent events and developments may cause views and expectations to change. The Company assumes no obligation, and specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
AcuityAds Holdings Inc. (TSX: AT) (OTC: ACUIF) ("AcuityAds" or "Company"), a technology leader that provides targeted digital media solutions enabling advertisers to connect intelligently with audiences across digital advertising channels, today announced that Tal Hayek, Co-Founder and CEO, will be hosting one-on-one investor meetings, at the 16th Annual Needham Virtual Technology & Media Conference.
The worldwide public cloud services market grew 24.1% year over year in 2020 with revenues totaling $312 billion, according to IDC.
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2021) - Fremont Gold Ltd. (TSXV: FRE) (OTCQB: FRERF) (FSE: FR2) ("Fremont" or the "Company") announces the resignation of Blaine Monaghan as President and CEO of the Company, effective immediately. The Board thanks Mr. Monaghan for his efforts.Dennis Moore, has agreed to assume the role of CEO on an interim basis, effective immediately. Mr. Moore is the Company's President, and is one of the founders of Fremont ...
VANCOUVER, British Columbia, May 13, 2021 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO & NVO.WT; OTCQX: NSRPF) is pleased to advise that it has completed its option exercise to earn a 50% interest in the Malmsbury gold project (the “Malmsbury Project”) held by ASX-listed GBM Resources Limited (ASX: GBZ) (“GBM”) following the satisfaction of all conditions precedent, including receipt of Australian Foreign Investment Review Board approval (refer to the Company’s news releases dated March 30, 2020, September 24, 2020, and January 15, 2021 for further details). "We are thrilled to complete our option exercise at Malmsbury," commented Dr. Quinton Hennigh, Chairman and President of Novo. "We see Malmsbury as a Fosterville analogue given its similar position along the eastern margin of the prolific Bendigo Zone, epizonal orogenic setting and historic high-grade gold production. Our geologic team will pursue aggressive field work over the next few months with the goal of developing drill targets for testing later this year." Novo has issued 1,575,387 common shares (the “Option Shares”) to GBM as consideration for the exercise of the option. The Option Shares are subject to a statutory hold period expiring on September 14, 2021. The Company has also reimbursed GBM for AUD $250,000-worth of exploration expenditures on the Malmsbury Project, with such reimbursed amount being credited against the Earn-In Amount (defined below). Novo now has the right to earn an additional 10% interest in the Malmsbury Project and form a joint venture with GBM by incurring AUD $5 million in exploration expenditure (the “Earn-In Amount”) over a four-year period (the “Earn-In Period”), as to a minimum of AUD $1 million during the first year, and AUD $1.25 million in each subsequent year, of the Earn-In Period. Any expenditure incurred during any year of the Earn-In Period which surpasses the minimum required amount will be credited against the subsequent year’s commitment. If Novo does not satisfy the Earn-In Amount during the Earn-In Period, Novo’s interest in the Malmsbury Project will decrease to 49%. If Novo satisfies the Earn-In Amount during the Earn-In Period and delivers to GBM written notice of its election to increase its interest in the Malmsbury Project to an aggregate 60% interest and initiate a joint venture with GBM (the date on which such notice is given being the “Joint Venture Date”), GBM will be required to elect to (i) retain its 40% interest in the Malmsbury Project by contributing to 40% of exploration and development expenditure incurred subsequent to the Joint Venture Date, or (ii) dilute its interest in the Malmsbury Project to 25% upon delivery by Novo of a preliminary economic assessment (the “PEA”) disclosing at least a 1 million ounce gold resource on the land covering the Malmsbury Project, of which at least 60% must be in the Indicated classification, within 3 years from the Joint Venture Date. In such case, Novo will pay all development expenditure incurred commencing from the Joint Venture Date, but if a decision to mine is made, GBM will reimburse Novo as to 25% of any such development expenditure from a maximum of 80% of Malmsbury Project cash flows. Novo and GBM have also executed a royalty arrangement whereby, subsequent to a decision to mine (if made), GBM is entitled to receive a maximum 2.5% net smelter returns royalty (the “Maximum Royalty”). The Malmsbury Project is encumbered by certain pre-existing royalties; where such an encumbrance is present, GBM will only be entitled to an adjusted royalty, being the Maximum Royalty less any pre-existing royalty amount. Dr. Quinton Hennigh (P.Geo.) is the qualified person pursuant to NI 43-101 responsible for, and having reviewed and approved, the technical information contained in this news release. Dr. Hennigh is the president, chairman and a director of Novo. About Novo Resources Corp. Novo is commissioning its flagship Beatons Creek gold project while exploring and developing its highly prospective land package covering approximately 14,000 square kilometres in the Pilbara region of Western Australia. In addition to the Company’s primary focus, Novo seeks to leverage its internal geological expertise to deliver value-accretive opportunities to its shareholders. For more information, please contact Leo Karabelas at (416) 543-3120 or e-mail email@example.com On Behalf of the Board of Directors, Novo Resources Corp. “Quinton Hennigh” Quinton Hennigh President and Chairman Forward-looking information Some statements in this news release contain forward-looking information (within the meaning of Canadian securities legislation). These include statements (the “forward-looking statements”) regarding Novo’s intent, or the beliefs or current expectations of Novo’s management. When used in this news release, words such as “will”, “would”, “expect”, “target”, “potential”, “objective”, “subject to”, “expected to” and similar words or expressions identify these forward-looking statements as well as phrases or statements that certain actions, events or results “may”, “could”, “would”, “should”, “occur” or “be achieved” or the negative connotation of such terms. Forward-looking statements in this news release include but are not limited to the successful completion of the Earn-In Amount during the Earn-In Period, the successful completion of the PEA, and that Malmsbury is seen as a Fosterville analogue. Forward-looking statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, without limitation, the risk factors identified in Novo’s annual information form for the 11-month financial year ended December 31, 2020 and Novo’s management’s discussion and analysis for the same period, both of which are available on SEDAR at www.sedar.com. Forward-looking statements speak only as of the date those statements are made. Except as required by applicable law, Novo assumes no obligation to update or to publicly announce the results of any change to any forward-looking statement contained or incorporated by reference herein to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements. If Novo updates any forward-looking statement(s), no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.
Global Payments to Participate in Barclays Emerging Payments and Fintech Forum
NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions of Daxor’s BVA-100 Blood Volume Analyzer slated for Q3 2021 at major medical centers across the U.S. “Sales are accelerating as the COVID restrictions are relaxed at hospital centers, allowing our teams to resume on-site visits with customers, accelerating onboarding and the acquisition of our systems," said Jean Oertel, Vice President of Commercialization and Customer Experience. "We expect that we will have access to over 70% of our client hospitals by the end of Q2 2021. We anticipate that the ease of educating clinicians and providing hands-on training will further accelerate business in the ensuing quarters to come.” "As our commercial uptake is increasing, we have added additional resources to our sales and marketing team, having hired and trained three additional product representatives to our in-house team as we also work to increase access through third-party distribution agreements as well,” said Michael Feldschuh, President and CEO of Daxor Corporation. Jonathan Feldschuh, Chief Scientific Officer of Daxor noted, “The increase in sales and sales team members fit well with our planned next-generation analyzer product development schedule, which includes production of both nuclear and novel fluorescing-based point-of-care testing devices over the next year. Our next-generation system promises to be even faster, easier, and expand use of our test into more clinical settings for more indications, which we anticipate will be well-received by our expanding customer base." Daxor manufactures the BVA-100 blood test system which provides a simple, inexpensive, objective measurement of volume status and composition providing clinicians with actionable results to optimize fluid management and improve patient outcomes while driving substantial cost savings throughout the healthcare system. About Daxor Corporation Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Forward-Looking Statements Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Bret ShapiroSr. Managing Partner, CORE IR516firstname.lastname@example.org
Desjardins Global Asset Management Inc. ("DGAM"), as manager of the Desjardins Exchange Traded Funds, today announces the termination of Desjardins Canada Multifactor-Controlled Volatility ETF (TSX: DFC), Desjardins USA Multifactor-Controlled Volatility ETF (TSX: DFU), Desjardins Developed ex-USA ex-Canada Multifactor-Controlled Volatility ETF (TSX: DFD) and Desjardins Emerging Markets Multifactor-Controlled Volatility ETF (TSX: DFE) (collectively, the "Desjardins Multifactor-Controlled Volatility ETFs") as well as management fee reductions for Desjardins RI Canada - Low CO2 Index ETF (TSX: DRMC), Desjardins RI USA - Low CO2 Index ETF (TSX: DRMU) and Desjardins RI Developed ex-USA ex-Canada - Low CO2 Index ETF (TSX: DRMD) (collectively, the "Desjardins Cap-Weighted Low CO2 ETFs" and together with the Desjardins Multifactor-Controlled Volatility ETFs, the "Desjardins ETFs").
Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog semiconductors connecting people, places and things, today announced that David J. Aldrich has retired as the company’s chairman of the board and that Liam K. Griffin has been appointed to succeed him. Mr. Griffin will continue to serve as president and CEO of Skyworks. The board’s lead independent director, Christine King, will also continue to serve in her current role.
Intouch Insight Ltd. ("Intouch" or the "Company") (TSXV: INX) (OTC: INXSF) today announces that on May 12th it has signed a non-binding Letter of Intent ("LOI") to purchase the assets of an arm's length North American customer experience measurement company (the "Vendor"), subject to TSX Venture Exchange approval (the "Acquisition"). For reasons of competition and privacy Intouch will not disclose the name of the Vendor until the completion of a definitive agreement. The targeted closing date is September 1, 2021. The Vendor has approximately USD $5.0M in revenues with a gross margin of 41%.
Idea Grove has been named to Inc. magazine’s annual list of the Best Workplaces for 2021.